Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BTH
These analysts are betting that ARIA will have a strong showing at ASCO. That’s not exactly stick their neck out now is it? LOL most analyst opinions are worthless! I would venture to say many at this board can give better guidance.
Not the Cramer curse.
Big Money's Faviorite Growth Stocks
Some Bio stocks are listed here. (PACB) (EXAS) (SQNM) (ARIA) 2 medical device stocks (NXTM) (PODD).
http://seekingalpha.com/article/269293-the-big-money-s-favorite-growth-stocks?source=email_watchlist
Proxy Vote
Anyone else receive this yet? Do you know anything about the people they are requesting be appointed to the BOD?
ARIAD PHARMACEUTICALS, INC.
2011 Annual Meeting of Shareholders
To be held on 06/23/2011 for holders of record as of 04/28/2011
Recommendations of the Board of Directors:
Choose this option if you would like to vote your shares with the recommendations of the Board of Directors. See below or refer to the proxy statement for details on the recommendations.
Please be advised that this agenda contains an item for you to record your preference on how often you would like to vote on Executive Compensation.
Vote with the Board's Recommendations
Proposal(s) Recommendations of the Board of Directors Vote Options
01 DIRECTOR
1) JAY R. LAMARCHE
2) NORBERT G. RIEDEL, PHD.
3) ROBERT M. WHELAN, JR.
For For All Nominees
Withhold All Nominees
For All Except Selected Below 1) JAY R. LAMARCHE
2) NORBERT G. RIEDEL, PHD.
3) ROBERT M. WHELAN, JR.
02 TO RE-APPROVE THE PERFORMANCE OBJECTIVES AND OTHER APPLICABLE PROVISIONS SET FORTH IN OUR 2006 LONG-TERM INCENTIVE PLAN, AS AMENDED, FOR PURPOSES OF COMPLYING WITH SECTION 162(M) OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED
For For Against Abstain
03 TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2011
For For Against Abstain
04 TO CONSIDER AN ADVISORY VOTE ON COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT
For For Against Abstain
05 TO CONSIDER AN ADVISORY VOTE ON THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
3 Years 1 Year 2 Years 3 Years Abstain
2damoon1
Good Job on the Surveys. Thanks for taking the time to make them.
KF
Kimble
QUOTE
_________________________________________________________________
what does that change??
ALTOUNIAN put togehter the PPMS at 6 , 4 and 2.5 cents...
I participated in them,,,,,saw this was a scam....and sold as soon as my restrictions where lifted....i have been telling everyone about this ever since
______________________________________________________________
Since you asked the question, I will give my opinion here:
I think any PPM shareholder/ or insiders involved will be questioned in the SEC,FBI,FDA,FINRA and any agencies that I may have omitted, investigation that many speak of here if it comes to pass.
KF
Quote
-----------------------------------------------------------------
There seems to be and I don't understand why there is so much surrounding the infamous . Why will it be any different then all of the other BS Dean Janes has thrown our way? I am more interested in the 10Q about to surface because I just know it will be real bad news. ;)
------------------------------------------------------------------
"irrational exuberance" No lack of this?
"May 13th video"
You have asked at this board for Dean to provide evidence?
Now you make these statments? I dont understand?
Help Me/ Help Us/ understand your previous post?
KF
Mugs
I welcome your posting the response from the Ombudsman. Can you post it when you receive it? Less your personal info?
I have researched the FDA more than I ever intended. Some amazing facts I found were: The FDA has no power to levy fines or jail time. The FDA has no power other than to approve/deny a device or drug. They can recall both. If a company does not comply, the FDA can only call the Federal Marshals to do the work. The Federal Marshalls will confiscate either and remove from market. The only Teeth the FDA has is in decisions rendered. Another toothless Archaic agency.
Any thoughts on why the SEC is so inactive? They are granted much more leeway. They do have judiciary power.
KF
You could be correct. What do you think we will see within Proof of Concept "guidlines" I think this phrase came from the FDA?
KF
What I read in the FDA rules, the FDA will not permit any professional Radiologist or Dr. to give their view within the rules in the video unless previously approved.
This is why I have asked every investor to get a local Radiologist point of view. I doubt the FDA will permit anything other than a scientific demonstration of the DVIS.
GLTA
KF
Former Marine
I think from everything I have read in the FDA regulations, the FDA will limit what Imaging 3 will be permittted to show in the video. As Muggsy stated previously read the Ibox post I made some time ago. Its a letter from Eva Ellsworth that actually works at the FDA. All Contact information is included in the emails. I removed my personal info for obvious reasons.
Here is the link to the letter from the FDA
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60367647
KF
stockmasterflash
What would you need to see in the Demo to convince you that the DVIS exist and performs?
Mugs, I ask you the same question?
KF
Flash
It matters not to me where the technology is aired. Only the factual content. I will make my decisions based on the Demo, but we have not seen it yet. Who knows what we will see? I suggest we wait until its aired. The demo has been asked for over 1000 times here alone. Whats a few more days.
I feel the same about the content at this message board. Are you embarrassed here?
KF
I have a top of the line University Hospital near me. I plan to get a person I know there in the Radiology Department to view the Demo. I won’t reveal the name of the Hospital or Radiologist for fear of relentless phone calls to them.
Looking forward to May 13 DVIS DEMO
I will wait until May 13 to see the video and get a professional to render their opinion. I do realize we have very few professional people in the radiology field that post at the board. I think this is obvious to most.
I suggest to all: get an opinion from someone you know locally. There are shareholders from all over this country invested in IMGG. Only about 250 read this board of opinions. Get a professional opinion and make your decision based on that diagnosis. I won't make my decision based on what is posted here by laymen’s. I will ask my local Radiologist for their opinion. I suggest everyone do the same.
GLTA
KF
ARIA NEWS Pace Trial ahead of Schedule
ARIAD Reports First Quarter 2011 Financial Results and Development Progress
Ariad (NASDAQ:ARIA)
Intraday Stock Chart
Today : Thursday 5 May 2011
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the three-month period ended March 31, 2011 and provided an update on corporate developments. An investor conference call and webcast will be held tomorrow at 8 a.m. (EDT).
“We have had an excellent quarter with uniform progress taking place throughout our most advanced programs,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “We and our partners are advancing the clinical development of our internally discovered small-molecule drug candidates. The PACE trial of ponatinib is enrolling patients substantially ahead of schedule, and positive, Phase 3 clinical data on ridaforolimus will be presented at the ASCO meeting on Monday, June 6. We anticipate that the first two ARIAD-discovered cancer drugs may be on the market and available to cancer patients by late next year.”
PACE Trial Ahead of Schedule
Patient enrollment in the pivotal Phase 2 PACE trial of ponatinib, ARIAD’s investigational pan-BCR-ABL inhibitor, is well ahead of schedule, and full patient enrollment, including over-enrollment in some patient cohorts, is expected to take place in the third quarter of this year, almost six months earlier than initially anticipated. The PACE trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to either of the second-generation CML therapies, or those who have the T315I mutation of BCR-ABL, for which no current treatments are known to be effective.
Patient enrollment in the trial is progressing in all patient cohorts, including those patients with the T315I mutation. ARIAD now anticipates filing for marketing approval of ponatinib in the middle of next year, providing the potential for approval by the end of 2012.
Importantly, as a result of the speed at which patients are being enrolled in the PACE trial and earlier availability of follow-up data on patient outcomes, ARIAD is planning to submit comprehensive interim data from the trial this summer – a year ahead of schedule – for presentation at the annual meeting of the American Society of Hematology (ASH) that will take place late this year.
In addition, preliminary clinical data from a group of patients with FLT3-positive acute myeloid leukemia who were treated with ponatinib as part of its ongoing Phase 1 trial will be presented at the American Society of Clinical Oncology (ASCO) meeting on Friday, June 3.
“We are extremely proud of the progress that is taking place in the global development of ponatinib,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer. “The expedited rate of patient enrollment in the PACE trial highlights that there is definite, unmet medical need in CML and that new treatments are necessary to help patients who have become resistant or intolerant to the earlier generation drugs.”
SUCCEED Trial Data to Be Presented at ASCO
Comprehensive data from the completed Phase 3 SUCCEED trial of oral ridaforolimus in patients with metastatic soft-tissue and bone sarcomas will be presented in an oral session at the ASCO meeting on Monday, June 6, 2011, at 4:30 p.m. (CDT), including data on the primary and secondary endpoints and data from predefined patient sub-analyses in the trial. ARIAD expects its partner, Merck, to file for regulatory approval of ridaforolimus in the U.S. and in Europe later this year. If approved, ridaforolimus would be the first molecularly targeted treatment for patients with sarcomas.
ARIAD exercised its option with Merck in the first quarter of the year to co-promote ridaforolimus with up to 20 percent of the sales effort in the United States. This provides ARIAD with a direct involvement in the potential commercial success of ridaforolimus and, at the same time, lays the groundwork for the sales and marketing infrastructure that will be utilized by ARIAD for the future commercialization of ponatinib.
AP26113 Advancing to the Clinic
ARIAD expects to file an investigational new drug application for AP26113, its investigational anaplastic lymphoma kinase (ALK) inhibitor, in the middle of this year and to begin a biomarker-based clinical trial shortly thereafter. AP26113 was specifically designed by ARIAD scientists as a highly potent inhibitor of ALK with superior drug-like properties and best-in-class potential. Multiple tumor types, including certain non-small cell lung cancers, lymphomas and neuroblastomas, are driven by aberrant ALK activation. In preclinical studies, AP26113 has been shown to be substantially more potent than crizotinib, Pfizer’s investigational ALK inhibitor, and to completely suppress resistance that is now being seen in the clinic with crizotinib.
ARGENT Cell-Signaling Regulation Technology Out-Licensed
ARIAD completed three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology. These agreements leverage ARIAD’s early investment in this innovative science, while providing the company with value linked to equity stakes, milestones, royalties and up-front payments and fees. ARIAD and Bellicum Pharmaceuticals, Inc. expanded their previous agreement as a result of promising clinical data from Phase 1/2 trials of Bellicum’s ARGENT-regulated cancer vaccine and cell-therapy product candidates, both utilizing AP1903, a small-molecule dimerizer drug discovered and developed by ARIAD. ARIAD and ReGenX Biosciences, LLC established a collaboration to combine the ARGENT technology with ReGenX’s proprietary gene-delivery technology for development of gene therapy products with pharmacologic control of gene expression and the potential for greater safety and efficacy in certain disease applications. Lastly, Clontech Laboratories, Inc. has assumed full responsibility for supplying the ARGENT technology worldwide for research applications, expanding its availability to scientists for in vitro and in vivo use.
Financial Highlights
For the three months ended March 31, 2011, ARIAD reported a net loss of $37.9 million, or $0.29 per share, compared to a net loss of $23.4 million, or $0.21 per share, for the corresponding period in 2010. The increase in net loss is primarily due to an increase of $12.5 million in the non-cash charge related to the revaluation of the company’s warrant liability from $6.1 million in the first quarter of 2010 to $18.6 million in the first quarter of 2011. The charge is primarily attributable to an increase in the market price of ARIAD’s common stock from $3.40 per share at March 31, 2010 to $5.10 per share at December 31, 2010 and $7.52 per share at March 31, 2011.
In addition, ARIAD’s net loss reflects a decrease in revenue of $2.1 million, due primarily to the restructuring in May 2010 of the company’s collaboration with Merck for the development and commercialization of ridaforolimus. Also, the Company’s operating expenses remained steady at $19.4 million in both the first quarter of 2010 and the first quarter of 2011, reflecting the net effect of a decrease in expenses for development of ridaforolimus as a result of the restructuring of the company’s agreement with Merck and an increase in expenses related to development of ponatinib due to increasing enrollment of patients in clinical trials.
For the three-month period ended March 31, 2011, cash used in operations was $17.3 million, compared to cash used in operations of $14.3 million for the corresponding period in 2010. In addition, cash flows for the first quarter of 2011 included $7.6 million in proceeds from the exercise of warrants and $4.4 million in proceeds resulting from an amendment to ARIAD’s term-loan agreement. The Company ended the first quarter of 2011 with cash and cash equivalents of $98.4 million, compared to $103.6 million at December 31, 2010.
Upcoming Medical Meetings
2011 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3 to 7, 2011.
14th World Conference on Lung Cancer, Amsterdam, The Netherlands, July 3 to 7, 2011.
Upcoming Investor Meetings
Bank of America Merrill Lynch 2011 Healthcare Conference, Las Vegas, NV, May 10 to 12, 2011.
Jefferies 2011 Global Life Sciences Conference, New York, NY, June 6 to 9, 2011.
Tomorrow’s Conference Call Reminder
ARIAD will hold a live webcast of its quarterly conference call tomorrow, May 5, 2011 at 8 a.m. (EDT). The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ariad.com%2Finvestor&esheet=5946762&lan=en_US&anchor=http%3A%2F%2Fwww.ariad.com%2Finvestor&index=3 The call can be accessed by dialing 866-831-6267 (domestic) or 617-213-8857 (international) five minutes prior to the start time and providing the pass code 15820400. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit http://www.ariad.com.
This press release contains “forward-looking statements” including, but not limited to, updates on clinical, preclinical and regulatory developments for our three product candidates. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, preclinical data and early-stage clinical data that may not be replicated in later-stage clinical studies, the costs associated with our research, development, manufacturing and other activities, the conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
In thousands, except per share data Three Months Ended
March 31,
2011 2010
(Unaudited) (Unaudited)
Total revenue $ 56 $ 2,154
Operating expenses:
Research and development 14,574 14,835
General and administrative 4,854 4,574
Total operating expenses 19,428 19,409
Revaluation of warrant liability (18,572 ) (6,080 )
Other (5 ) (63 )
Other income (expense), net (18,577 ) (6,143 )
Net loss $ (37,949 ) $ (23,398 )
Net loss per common share
$ (0.29 ) $ (0.21 )
Weighted average number of shares of common stock outstanding
128,998 109,016
CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION
In thousands March 31,
2011
December 31,
2010
(Unaudited)
Cash and cash equivalents $ 98,356 $ 103,630
Total assets $ 115,032 $ 120,030
Working capital $ 84,988 $ 88,775
Total liabilities $ 62,980 $ 55,954
Stockholders’ equity $
52,052 $ 64,076
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION
In thousands Three Months Ended
March 31,
2011 2010
(Unaudited) (Unaudited)
Net cash used in operating activities $ (17,269 ) $ (14,327 )
Net cash used in investing activities (664 ) (342 )
Net cash provided by (used in) financing activities 12,659 (251 )
Net decrease in cash and cash equivalents $ (5,274 ) $ (14,920 )
Kimble
Quote
----------------------------------------------------------------
if any of you are around this year you have to go....it will speak volumes
----------------------------------------------------------------
Just don’t go at 1200 hrs when everyone is at lunch and expect to see crowds of people everywhere? They have to eat.
Great post BTW and 1200hrs avatar?
Its amazing how the post count is increasing on the eave of the Dominion DEMO. What is causing this? Are some having second thoughts? Just asking.....
KF
Mr Sano
I hope he replys. Did you ask if he would give his professional view of the upcoming Dominion Demo?
I would love to hear a highly educated Dr. from an accredited Universities point of view. Please ask him if you can post his response at the board for all to view. Can you post your email to him for the board to read?
KF
Flash
I agree to an extent. Why does it matter where the Demo is aired as long as the public can see it? It has been asked for no less than 1000 times at this board alone. Good or bad, there will be many points of view in what is seen.
I plan to ask a Radiologist friend of mine to view it because I'm a layman. I want a professional opinion.
BTW I was not putting you on the spot with my question about any IMGG SEC investigations, I was serious. Have you found anything?
KF
Kimble
I for one have never called anyone a liar at the board. I rely on verifiable facts and sometimes question phone calls to anonymous people, or unsubstantiated facts. I think all readers should question the validity of every post pro or con.
I do feel you ask others to do the work in your post. You seem to take a pessimist stance, that’s fairly easy to do. I have seen no verifiable DD you have produced? Why not post facts instead of questions? A little more difficult to accomplish, but something worth posting that the board would actually consider.
KF
aria2010
Place a GTC order at a low price that you think it may go to. I have had mine in place for nearly a month now. I continue to hold my core position, but this stock trades well also.
GLTA
KF
I agree Jacquie.
I hope the FDA allows Dean to show this Demo in a scientific manner. This could prove that there is a Dominion producing 3D images to all but a handful. Time will tell who has spoken the truth. I plan to let my Radiologist view the Demo and give me his professional point of view. I know as a layman, I won’t be able to ascertain the full impact of what I see in the video. I'm not a Dr, Radiologist or even in the industry as some pose here?
KF
Mr. Sano
Do you know anything about the 20-20 investigation that was mentioned here? Dean has stated he is going to show a Demo of the Dominion. This is a prime time for who ever mentioned it here to contact 20-20 once again? What better opportunity than now to have a Top National Investigational Team on site? We could possibly get someone that actually holds a PHD point of view?
Hello Flash
Have you found any information where Imaging 3 is under SEC investigation? I continue to check my sources but have found nothing. I will be the first to post it if I do.
KF
KK Guru
Great information. Im looking forward to reading the entire article as well as the Dominion Demonstration.
KF
Jacquie
Thank you for the article.
New Survey
It was mentioned a few days ago about a new survey. Anyone have suggestions? I will break the ICE with a difficult question that some don’t want to consider:
When you do the next survey I think this question should be included; At what pps will ARIA dilute? Give some parameter numbers to choose from.
I think the board has done well in past surveys. It seems we were very accurate with our votes from the past, in the outcome to present.
KF
Flash
I understand your point of view.
I have a new found respect for elementary school teachers. I have experienced this myself. I feel they are way under paid!
I truly wish you the best. No pun.
KF
L6
I agree. Phone conversations from anonymous people hold no facts. Nothing more than hearsay and opinions IMO. Emails are written fact. I have found anything that is fact from and agency or Firm, they provide in writing with Name and contact information included.
Just one example here of many: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60367647
Pretty simple IMO
KF
adreamer
There is nothing wrong with having a positive outlook. In reality what we have is Pona on que for New Drug Application. The other compounds are still in various stages of trials. There is plenty of time for something to go wrong here. We must remember, we are dealing with the FDA and they make the final decisions. They have derailed many companys in the final stages.
Welcome madtig6
Great bunch of people here. I have found this board to be one of the best at the hub.
KF
IH Admin [Dan] Share Thursday, February 10, 2011 1:47:00 PM
Re: None Post # of 41014
Folks please stay on topic. The only topic to be discussed here is IMGG.
There have been too many deletions here recently. Please take time to read these rules so that you will understand why posts have been deleted:
http://ihwiki.advfn.com/index.php?title=Handbook#Deletion_of_Posts
Any time you post about Users or reference groups of Posters (bashers, pumpers, cheerleaders, naysayers, Mods, etc.) in your post, this makes your post subject to removal as off-topic and/or personal attack. Posts about deletions are also Off Topic.
Your messages need to focus on the company and the stock and should not contain comments about people who post on the board. Other posters are never the topic of the board.
To those who received restricted posting here for their TOU violations. In order to have that released you need to post for two weeks without violating the rules, then ask for Admin to review.
If you have any questions send me a PM.
NO public replies please.
IMGG NEWS
News for 'IMGG' - (Imaging3 CEO Dean James on MoneyTVI Interview Focuses on FDA Resubmission Strategy for Its 3D Real-Time Imaging Device)
Apr 15, 2011 (Close-Up Media via COMTEX) -- Imaging3, Inc., developer of a
medical imaging device that produces 3D medical diagnostic images of virtually
any part of the human body in real-time, announced that the company's Chairman
and CEO Dean Janes was interviewed on Thursday, April 7, on MoneyTV, a business
and investment oriented television program.
In a release, Imaging3 said the interview focused on the company's three phased
approach for its FDA 510(k) submission for the Dominion Volumetric Imaging
Scanner (DViS).
Janes said that the company has finalized its general resubmission strategy
after a thorough review with the company's FDA legal and technical consulting
team. Implementation of the strategy involves the following three phased
approach: First, the development of protocols for collecting comparison imaging
data. Second, with the assistance of the consultant team, meet with the FDA to
present the protocols with the goal of reaching consensus with the Agency to
help ensure a viable resubmission. The third and final phase is the acquisition
of images based on the approved imaging protocols and combining those images and
data with the overall package and final submission to the FDA.
More information:
http://www.imaging3.com
http://www.moneytv.net/imgg14.mov
http://www.moneytv.net/volume15week14.htm
((Comments on this story may be sent to newsdesk@closeupmedia.com))
Copyright Close-Up Media, Inc. 2011. All Rights reserved
-0-
INDUSTRY KEYWORD: Manufacturing_Close-up
IH Admin [Dan] Share Thursday, February 10, 2011 1:47:00 PM
Re: None Post # of 40991
Folks please stay on topic. The only topic to be discussed here is IMGG.
There have been too many deletions here recently. Please take time to read these rules so that you will understand why posts have been deleted:
http://ihwiki.advfn.com/index.php?title=Handbook#Deletion_of_Posts
Any time you post about Users or reference groups of Posters (bashers, pumpers, cheerleaders, naysayers, Mods, etc.) in your post, this makes your post subject to removal as off-topic and/or personal attack. Posts about deletions are also Off Topic.
Your messages need to focus on the company and the stock and should not contain comments about people who post on the board. Other posters are never the topic of the board.
To those who received restricted posting here for their TOU violations. In order to have that released you need to post for two weeks without violating the rules, then ask for Admin to review.
If you have any questions send me a PM.
NO public replies please.
Thank you ndforlife.
That explaines why the first patent is expired. The second one covers both. Is that correct?
KF
flash
They stated over the course of the next year. That means anytime over the next 12 months.
guest mike
IMO they don’t have enough cash. The S3 debacle caused I3 to miss out on the 1 mil in funding.
I think the FDA marketing rules will prevent Dean from showing investors much more than has been viewed in the past unless the FDA has given him permission.
The issues laid out in the NSE are resolvable imo.
Unknown
We are getting off topic in posting about company's other than IMGG. There are some great Ideas here, but at Ihub we must post on IMGG at this board, Please omit other stock symbols from your post. Ihub will delete them.